View
226
Download
2
Category
Tags:
Preview:
DESCRIPTION
Â
Citation preview
Company Profile
Lenus Pharma
Lenus Pharma GmbH (Ltd) is a fully privately owned and funded company, incor-porated under Austrian law and having its headquarters located at Seeböckgasse 59, A-1160 Vienna/Austria.
Lenus Pharma specialises in the research, development, marketing and distribution of nutraceuticals, according to European Union (EU) clas-sification named „foods for special medical purposes” (EU Commission Directive 1999/21/EC). The philosophy of the company is to develop
innovative products, meeting unmet medical needs, based on Evidence-based Medicine.
Beside product development and international market ex-pansion, Lenus Pharma is en-gaged in the local distribution and marketing of its own prod-uct range covering the urologi-cal, gynecological and ophthal-mological field in Austria and Slovakia.
Starting as the pioneer in the segment of Food for Special Medical Purpose especially for childwish, Lenus Pharma has developed to an international successful Pharma company.
Nam reperum de est, ex enessum ut veres pro volut perum as enist unditaturit remquassum delenda esendam re laborpor aliquas cus es rem
illaboratiam reperibus aut resciunt. Rum fugitem olorem de perite dio. Et etur, comnis audit, et odis et et aut autet iur sit lam dignis aperiatur, odis ea
voluptati sundandamus atquiandem as maio molecusantio
The art of holistic approach
The human and their desires, the human and their worries: Lenus Pharma has made to it´s aim to satisfy human ex-pectations. We do not look singularly at the medical components, but analyse the problem in its totality by looking at the whole person, including understanding its physical, nutritional, envi-ronmental, emotional, social, spiritual and lifestyle values.
All these components are driving and influencing the development of our prod-ucts. Our dedication to this holistic approach - together with our implicit wish of mak-ing people’s lives healthier - is the cornerstone of our success.
Only the best
GOOD MANUFACTURING
PRACTICE
is good enough.
We, at Lenus Pharma, focus on quality.
We are benchmarking ourselves not only according to our own high standards, but also to external, international guidelines for pharma-ceuticals.
Evidence Based Medicine EBM:
All products of Lenus Pharma are based on scientific and clinical studies, published in renowned journals.
Good Manufacturing Practice GMP:
All our products are produced in accordance with GMP, the highest quality standard for the production of pharmaceuticals. So from the selection of raw materials to the final product, we ensure the highest quality requirements.
1
GMP
PROfertil® for the dietary manage-ment of sub-fertility in men.
With PROfertil®, Lenus Pharma has successfully developed a nutra-ceutical (Food for Special Medical Purposes) for the treatment of male sub-fertility - supporting couples to overcome their long-lasting unful-filled desire for children.
With this specific nutraceutical com-bination the problems of sub-fertile men (quality, quantity and motility of sperm cells) are treated by its roots and can be improved in many cases.
The specific and study proven com-position of PROfertil® is adjusted to the special nutritional needs in the indicated area of application and meets particularly the increased nutrient requirements of men with diet-related sub-fertility.
– it’s the combination and
concentration of nutrients that
count
Product
Portfolio
PROfamily product line - for the dietary management of women from the wish for a child to lactation.
PROfertil® female - optimal preparation of the female body towards pregnancy.Fulfills the particular nutritional requirements of women with child-wish until the end of the third month of pregnancy.
PROpregna®- the ideal compensation in an intensive period of life.Fulfills the particular nutritional requirements of women during pregnancy.
PROglanat® - nutritional supply during lactation period at the best.
PROfamily – from the wish for a child to the child of your wish!
Product
Portfolio
PROSTAvital® for the dietary management of men with prostate cancer or other benign or
malignant disorders of the prostate.
Prostate problems are among the most common accompanying symptoms of the aging process in men.
About one third of men over 50 years struggle with prostate problems and prostate cancer has already become one of the most prevalent cancer in men.
PROSTAvital® - Victory for life!
PROmacula® product line - PROmacula® areds, PROmacula® max!, PROmacula® lutein and PROmacula® omega for the dietary management of Age-related macular degeneration
(AMD).
With the PROmacula® line of products, Lenus Pharma has successfully managed to develop a Food for Special Medical
Purpose (FSMP) for persons with advanced age-related macular degeneration.
It was the first product in Austria and is the only complete product line for the indication of AMD, which is in line with the
A.R.E.D.S. study and thus preserves the eyesight.
PROmacula® lutein fully complies with the A.R.E.D.S 2 study.
PROmacula® – and brightness remains!
PROSTAvital® for the dietary management of men with prostate cancer or other benign or
malignant disorders of the prostate.
Prostate problems are among the most common accompanying symptoms of the aging process in men.
About one third of men over 50 years struggle with prostate problems and prostate cancer has already become one of the most prevalent cancer in men.
PROSTAvital® - Victory for life!
– it’s the combination and
concentration of nutrients that count
®
®
®
History ofPROfertil®
Based on the increasing awareness of male fertility problems, a fruitful cooperation with doctors and researchers of the Vienna University Hospital has started in 2002 with the goal to develop an innovative product which improves male fertility.
Following a period of compound-analysis, efficacy-screening and development-studies in the search for the
ideal combination of nutrients, the pilot study was finally designed in 2005. In course of the product development, the Vienna University Hospital also conducted this pilot study which convincingly showed significant positive results already for the first interim-analysis!
In 2006, PROfertil® had become ready for patent application and serial-production and was notified in Austria as the first EU country, according to EU Directive 1999/21/EU on Foods for Special Medical Purposes.
PROfertil®Patents
PROfertil® is a patented product with worldwide patent granted. Austrian Patent – 503 219 2008
Eurasian Patent – 015422 2011
European Patent – 1 978 949 2012
US Patent – 13/575,027 pending
PROfertil® is a registered trademark in Austria, European Union, the US, the Middle East and Asia.
Studies and representation ofPROfertil®
Study Number of patients
Published/presented
1. Pilot study2006-2008:
„Micronutrients change the influence
of sperm quality in fertility”
120 EAU Bratislava 2010
2. Varicocele study 2009:
“Micronutrients as analternative to fertility
treatment in menwith subclinical
varicocele”
51
Fortbildungstagung der österr. Gesells-
chaft fürUrologie und Androlo-
gie mitJahreshauptver-
sammlung der ÖGU Linz 2010;
EAU Bratislava 2010
3. Controlled study2010:
„Improvement ofsperm quality after
micronutrientsupplementation
205( 132 therapy
group,73 control
group)
e-SPEN, the European e-Journal of Clinical
Nutrition and Metabo-lism Vol. 7 Issue 1 (December 2011)
&European Urological Review Volume 6 Is-
sue 2
4. DNA-study2010-2011:
“Sperm DNA fragmen-tation decreases after micronutrient supple-
mentation”
107(67 therapy
group, 40 control
group)
Menopause/Andropause and
Anti-Aging Congress Vienna
(December 2011)Poster presentation
The goal of Lenus Pharma is continuously providing studies of our products based on the latest scientifical standard. From the first pilot study of PROfertil® onwards, the medical team of Lenus Pharma is steadily working on new studies in cooperation with specialists.
In 2010 the positive results of the pilot study (2006 -2008, with 120 patients) and also the data of a new varicocele study (2009, with 55 patients) were presented at the 10th Central European Meeting (CEM) of the European Association of Urology in Bratislava/Slovakia.
In December 2011 the controlled study of PROfertil® - Improvement of sperm quality after micronutrient supplementation –was published in the e-SPEN, the European e-Journal of Clinical Nutrition and Metabolism, Vol. 7 Issue 1.
During the Menopause/Andropause and Anti-Aging Congress in Vienna (December 2011) the first significant results of the latest study on PROfertil® were presented at the poster-session under the title – Sperm DNA Fragmentation Index Decreases After Micronutrient Supplementation.
Own studies and continuous research have been the backbone of the success of PROfertil®. Therefore further studies on PROfertil® are planned for the near future in order to increase PROfertil®’s position as the most evidence-based male fertility product on the international markets.
Outlook and future prospects:
Study in process: Double blind, controlled multi-center study – PROfertil vs. one of the most investigated single substance (with partly survey of DNA).
PROfertil®International
2006 Austria
2006 Slovakia
2007 Azerbaijan
2008 Latvia
2008 Estonia
2008 Lithuania
2008 Czech Republic
2008 Kosovo
2009 Germany
2009 Ukraine
2009 Albania
2010 Russia
2010 Serbia
2011 Italy
2011 Georgia
2012 Romania
2012 Turkey
2012 Spain
2012 Libya
2012 Netherlands
2012 Tunisia
2012 Kuwait
2012 Bosnia& Herzegovina
2012 Macedonia
2012 Montenegro
2012 Greece
PROfertil® available in:(May 2013)
2013 Hungary
2013 Poland
2013 Rep. of Korea
2013 Taiwan
2013 Saudi Arabia
2013 Bulgaria
2013 Iraq
2013 Jordan
2013 UAE
Early in 2007, Lenus Pharma started its international expansion with PROfertil® and gained increasing popularity. Since our strategy is to have a constant and steady expansion with well selected Distribution partners, the company has gone through a successful and continuous growth on the international market.
Lenus Pharma is regularly represented at the following international medical congresses:
• EAU - Congresses of the European Association of Urology
• ESHRE - Congresses of the European Society of Human Reproduction and Embryology
• AUA - Congresses of the American Urological Association
• MEFS - Congresses of the Middle East Fertility Society
• Arab Health
• ASA - Congresses of the American Society of Andrology
• COGI - World Congresses on Controversies in Obstetrics, Gynecology and Infertility
Besides international congresses, Lenus Pharma is participating at major medical congresses in the fields of Urology, Gynecology and Human Reproduction in its home markets Austria and Slovakia.
Status as of May 2013
SocialResponsibility
Social engagement is an important matter of concern to us, therefore Lenus Pharma supports several social and charity organizations, which have the aim to support life and health:
Sponsor of the Life Ball – “Clinton Health Access Initiative (CHAI) ” of the William J. Clinton Foundation
Special Olympics
Fertility Europe - European umbrella association of 31 European country organizations and associations dedicated to fertility issues.
Austrian Cancer Aid
Austrian fundraising campaign “Licht ins Dunkel”
Support for the University Teaching Hospital, Lusaka/Zambia
Local events
Lenus Pharma/Managing Partner
Rewards
09/2006: Woman Award Austria for outstanding success in Innovation
06/2007: Austrian most innovative company
09/2007: Great Women of the 21st Century Award (US)
Contact
For more information about Lenus Pharma and our products, please contact:
Lenus Pharma GmbH, Seeböckgasse 59, A-1160 Vienna/Austria,
t: +43 (1) 405 14 19f: +43 (1) 405 14 19 - 20
m: office@lenuspharma.comw: www.lenuspharma.com
Company Register No. FN 282292k at the Commercial Court, Vienna. Company Profile, May 2013
Recommended